Last reviewed · How we verify
NCT05888766
Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg
trial testing Rimegepant 75 milligrams in Migraine Disorders in 20 participants. Status unknown.
30 July 2024
Quick facts
| Lead sponsor | University of Roma La Sapienza |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 July 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Rimegepant 75 milligrams — full drug profile →
Conditions studied
- Migraine Disorders — all drugs for Migraine Disorders →
Sponsor
University of Roma La Sapienza
Who can join
Adults 18 to 65, any sex, with Migraine Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tools to predict which patients could better respond to abortive CGRP target therapy are still lacking. We propose to investigate if biochemical (salivary CGRP) and neurophysiological (evoked potentials) biomarkers can recognize patients with the best chances of responding to Rimegepant 75 mg as an acute treatment of migraine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05888766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine Disorders
Currently open trials in the same condition.
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
- NCT07093138 — Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatmen · Phase 4 · recruiting
- NCT06426316 — The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. · NA · recruiting
- NCT06623188 — Treatment of Episodic Migraine With AURICular Neuromodulation · NA · recruiting
- NCT06535880 — Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas As Well As Subnuclei of the Spinal Trigeminal Nucleus · NA · recruiting
Other University of Roma La Sapienza trials
Trials by the same sponsor.
- NCT07485023 — Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation · NA · not yet recruiting
- NCT07305519 — The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin · NA · not yet recruiting
- NCT07520968 — ABX Versus CHX in NSPT: a RCT · NA · active not recruiting
- NCT07109596 — Integration of Clinical, Biological and Psycho-social Variables for a Gender-sensitive Frailty Prediction · recruiting
- NCT07490574 — Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05888766 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Roma La Sapienza
- Last refreshed: 5 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05888766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing